| Title | Author(s) | Year | View Count |  | Telbivudine versus lamivudine in patients with chronic hepatitis B | Lai, CL; Gane, E; Liaw, YF; Hsu, CW; Thongsawat, S; Wang, Y; Chen, Y; Heathcote, EJ; Rasenack, J; Bzowej, N; Naoumov, NV; Di Bisceglie, AM; Zeuzem, S; Moon, YM; Goodman, Z; Chao, G; Constance, BF; Brown, NA | 2007 | 258 |
 | HBV resistance determination from the telbivudine globe registration trial | Standring, DN; Seifer, N; Patty, A; Chapron, C; Van Doorn, LJ; Chao, G; Brown, N; Lai, CL | 2006 | 122 |
| Effect of core promoter/precore mutation pattern and early virologic response on efficacy outcomes with telbivudine in HBeAg-negative chronic hepatitis B | Naoumov, N; Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Heathcote, EJ; Rasenack, J; Bzowej, N; Chao, G; Brown, N | 2006 | 106 |
| Telbivudine displays consistent antiviral efficacy across patient subgroups for the treatment of chronic hepatitis B: Results from the GLOBE study | Thongsawat, S; Lai, CL; Gane, E; Chao, G; Fielman, B; Brown, N; GLOBE Investigator Group, . | 2006 | 136 |
| Phase III comparison of telbivudine vs lamivudine in HBeAg-positive patients with chronic hepatitis B: Efficacy, safety, and predictors of response at 1 year | Gane, E; Lai, CL; Liaw, YF; Thongsawat, S; Wang, YM; Cheng, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N | 2006 | 129 |
| A Randomized Trial of Telbivudine (LdT) vs Adefovir for HBeAg-positive Chronic Hepatitis B: Results of the Primary Week 24 Analysis | Heathcote, EJ; Chan, HL; Cho, M; Lai, CL; Moon, YM; Chao, YC; Myers, R; Minuk, G; Marcellin, P; Jeffers, L; Sievert, W; Kaiser, R; Chao, G; Brown, N | 2006 | 123 |
| Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patients | Zeuzem, S; Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N | 2006 | 124 |
| A randomized trial of telbivudine (LDT) vs. adefovir for HBeAg-positive chronic hepatitis B: Results of the primary week 24 analysis | Chan, HLY; Lai, CL; Cho, M; Heathcote, J; Moon, Y-M; Chao, Y-C; Myers, R; Minuk, G; Marcellin, P; Jeffers, L; Sievert, W; Kaiser, R; Chao, G; Brown, N | 2006 | 129 |
| Phase III Comparison of Telbivudine vs Lamivudine in Patients with Chronic Hepatitis B: Efficacy, Safety, and Predictors of Response at 1 Year | Bzowej, N; Lai, CL; Gane, E; Liaw, Y; Thongsawat, S; Wang, Y; Chen, Y; Heathcote, J; Rasenack, J; Naoumov, N; Chao, G; Fielman, B; Brown, N | 2006 | 124 |
| Maximal Early Hbv Suppression In Nucleoside-treated Hepatitis B Patients Is Associated With Optimal Virologic And Clinical Efficacy At One Year | Lim, SG; Lai, CL; Thongsawat, S; Wang, Y; Chen, Y; Rasenack, J; Naoumov, N; Chao, G; Brown, N | 2006 | 112 |
| Final results of a phase I/II dose escalation trial of valtorcitabine in patients with chronic hepatitis B. | Lim, SG; Lai, CL; Myers, M; Yuen, RMF; Wai, CT; Lyoyd, D; Pietropaolo, K; Zhou, XJ; Chao, G; Brown, NA | 2005 | 119 |
 | A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B | Lai, CL; Leung, N; Teo, EK; Tong, M; Wong, F; Hann, HW; Han, S; Poynard, T; Myers, M; Chao, G; Lloyd, D; Brown, NA | 2005 | 1,122 |
| Telbivudine (LdT) vs. lmivudine for chronic Hepatitis B: First-year results from the international phase III GLOBE trial | Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N; and the GLOBE Study Group, . | 2005 | 161 |
| Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (the GLOBE study) | Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N; and the GLOBE Study Group, . | 2005 | 162 |
| Final Results of a Phase I/II Dose Escalation Trial of Valtorcitabine in Patients with Chronic Hepatitis B | Lim, SG; Lai, CL; Myers, M; Yuen, RMF; Wai, CT; Lloyd, D; Pietropalolo, K; Zhou, XJ; Chao, G; Brown, NA | 2005 | 135 |
| Valtorcitabine provides potent suppression of hepatitis B virus in patients with chronic hepatitis B: Results of a phase I/II clinical trial. | Lai, CL; Brown, NA; Yuen, RMF; Wai, CT; Lloyd, D; Pietropaolo, K; Zhou, XJ; Chao, G; Lim, SG | 2004 | 178 |
| Results of a One-year International Phase IIB Comparative Trial of Telbivudine, Lamivudine, and the Combination, in Patients with Chronic Hepatitis B | Lai, CL; Leung, NWY; Teo, EK; Tong, M; Wong, F; Hann, HW; Han, S; Poynard, T; Myers, M; Chao, G; Lloyd, D; Brown, N | 2003 | 114 |
|
